Summary
Dr Paula Cunnea is an Advanced Research Fellow based in the Ovarian Cancer Action Research Centre, in the Division of Cancer. Paula leads a research group with Professor Christina Fotopoulou, focused on investigating tumour heterogeneity in high grade serous ovarian cancer, developing different 3D models of ovarian cancer, and applying different bioengineering approaches to cancer research. Paula also runs multiple multidisciplinary projects in the area of platinum resistance and development of novel therapeutics to target platinum resistance.
Paula initially joined the Ovarian Cancer Action Research centre in 2012, to work on a collaborative FP7 European Union funded project (Ovarian Cancer Therapy – Innovative Models Prolong Survival, OCTIPS), aiming to identify and characterise the cell population within an ovarian tumour that causes the patient to relapse, and to develop novel therapies in innovative model systems to combat the development of resistance to chemotherapy.
Paula obtained her primary BSc degree in Biomedical Science/Applied Science from Dublin Institute of Technology and Trinity College Dublin, Ireland, in 1997. Paula achieved her PhD in December 2006 following post-graduate research in the Karolinska Institute, Stockholm, Sweden. Paula worked as a postdoctoral researcher in National University of Ireland Galway and Queen's University Belfast, in particular in the Ovarian Cancer Research Laboratory of Dr Hilary Russell and Professor Peter Hall.
Publications
Journals
Cunnea P, Curry EW, Christie EL, et al., 2023, Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes., Cell Reports Medicine, ISSN:2666-3791, Pages:101055-101055
Cunnea P, Curry E, Christie E, et al., 2023, Spatial and temporal intra-tumoural heterogeneity in advanced High-Grade Serous Ovarian Cancer: implications for surgical and clinical outcomes, Cell Reports Medicine, ISSN:2666-3791
Yang Y, Li H, Fotopoulou C, et al., 2022, Toll-like receptor-targeted anti-tumor therapies: Advances and challenges, Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-37
Conference
Lythgoe M, Mullish B, Frampton A, et al., 2022, 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy, SITC 37th Annual Meeting (SITC 2022) Abstracts, BMJ Publishing Group Ltd
Ghisoni E, Benedetti F, Cunnea P, et al., 2022, Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer, ESMO Gynaecological Cancers Congress, ELSEVIER, Pages:S395-S395, ISSN:0923-7534